Carfilzomib (Kyprolis) Approved by FDA
(Onyx Pharmaceuticals, Inc., an Amgen Subsidiary)
On July 24, 2015, the U.S. Food and Drug Administration approved a new indication for Kyprolis® (carfilzomib) for injection.1 KYPROLIS can now be used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
| Trade Name |
Strength |
NDC* |
Pack Size |
Dosage Form |
| KYPROLIS |
60mg |
76075-0101-01 |
60mg X 1 Vial |
Injection, Powder, Lyophilized, for Solution |
*Note that the product’s NDC code has been “zero-filled” to ensure creation of an 11-digit code that meets CMS standards. The zero-fill location is indicated in bold.2
Please click here for full Prescribing Information for KYPROLIS: Full Prescribing Information If you require any additional information or have specific questions regarding this correspondence, please contact the Onyx Pharmaceuticals 360™ Program at 855-ONYX-360 (855-669-9360).
To see information from the FDA click here: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455873.htm
FDA Press Release:
The U.S. Food and Drug Administration approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.
A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones. The bone marrow is where normal blood cells are produced. In 2012, an estimated 21,700 people will be diagnosed with multiple myeloma and 10,710 will die from the disease, according to the American Cancer Society.
“The approval of Kyprolis provides a treatment option to patients with multiple myeloma whose disease has progressed despite use of available therapies,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research. “We are encouraged by the continued progress in the development of drugs for multiple myeloma over the past decade, offering improved treatment of this disease.”
The safety and effectiveness of Kyprolis, which is administered directly into a patient’s vein (intravenously), was evaluated in a study of 266 patients with relapsed multiple myeloma who had received at least two prior therapies, including Velcade and Thalomid (thalidomide).
The study was designed to measure the percentage of patients who experienced complete or partial disappearance of tumor after treatment (overall response rate). The overall response rate was 23 percent. The median duration of response was 7.8 months.
The most common side effects observed in more than 30 percent of the study participants were fatigue, low blood cell count and blood platelet levels, shortness of breath, diarrhea, and fever. Serious side effects seen with Kyprolis included heart failure and shortness of breath. Patients should be monitored closely and treatment withheld if these serious side effects occur.
The drug is being approved under the FDA’s accelerated approval program, which allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients. The program is designed to provide patients with earlier access to promising new drugs. The company is required to submit additional clinical information after approval to confirm the drug’s clinical benefit.
